Portola raises $89 million to go it alone with betrixaban
This article was originally published in Scrip
Portola Pharmaceuticals, a privately-held venture capital-backed company developing therapeutics for cardiovascular and immune diseases, has raised $89 million from new and existing investors to fund Phase III development of its blood thinner, betrixaban, and to develop a companion antidote product. The product was returned to Portola after Merck ended a collaboration in March.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.